How does anti-IL-6 receptor monoclonal antibody tocilizumab treatment ameliorate neuromyelitis optica?

被引：0
|
作者：
Matsuoka, T. [1 ,2 ,3 ]
Araki, M. [4 ]
Yamaguchi, H. [1 ]
Sato, W. [1 ]
Miyamoto, K. [5 ]
Kusunoki, S. [5 ]
Gold, R. [6 ]
Yamamura, T. [1 ,4 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Natl Inst Neurosci, Dept Immunol,Natl Ctr Neurol & Psychiat, Tokyo, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Dev Med Sci, Tokyo, Japan
[3] Natl Ctr Neurol & Psychiat, Tokyo Metropolitan Inst Neurosci, Child Brain Project, Tokyo, Japan
[4] Natl Ctr Neurol & Psychiat, Natl Ctr Hosp, Multiple Sclerosis Ctr, Tokyo, Japan
[5] Kindai Univ, Dept Neurol, Fac Med, Osaka, Japan
[6] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1755
引用
收藏
页码：1000 / 1001
页数：2
相关论文
共 50 条
  • [41] Anti-IL-6 receptor antibody treatment improves interstitial lung diseases in IL-6 transgenic mice
    Sugamata, Y
    Nakahara, H
    Katsume, A
    Sugimoto, M
    Yoshizaki, K
    Nishimoto, N
    JOURNAL OF LEUKOCYTE BIOLOGY, 2001, : 81 - 81
  • [42] A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD)
    de Seze, J.
    Kleiter, I.
    Fujihara, K.
    Palace, J.
    Greenberg, B.
    Zakrzewska-Pniewska, B.
    Patti, F.
    Tsai, C. -P.
    Saiz, A.
    Terada, Y.
    Kawata, Y.
    Wright, P.
    Yamamura, T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 985 - 986
  • [43] Treatment Resistant Neuromyelitis Optica Responsive to Anti IL-6 Immunotherapy
    Siwoski, Mark-Victor
    Lynch, Sharon G.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 120 - 120
  • [44] Atlizumab - Anti-IL-6 receptor antibody - Chugai, anti-interleukin-6 receptor antibody - Chugai, MRA - Chugai
    不详
    BIODRUGS, 2003, 17 (05) : 369 - 372
  • [45] Tocilizumab (Anti-IL-6 Receptor Antibody) and Intravenous Immunoglobulin (IVIG) in Difficult To Desensitize Patients: Phase I/II Trial
    Vo, Ashley
    Kim, Jua
    Kim, Irene
    Jordan, Stanley
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 : 49 - 49
  • [46] Research for anti-IL-6 receptor antibody, a novel anti-rheumatic agent
    Mihara, M
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 35P - 35P
  • [47] SOLUBLE FORM OF GP130 MOLECULE, AN IL-6 INHIBITOR, CONTRIBUTES THE EFFICACY ON RA TO TOCILIZUMAB (AN ANTI-IL-6 RECEPTOR ANTIBODY) THERAPY
    Yoshizaki, K.
    Song, S. N. J.
    Itoh, H.
    Iwahashi, M.
    Uno, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 716 - 716
  • [48] ANTI-IL-6 RECEPTOR ANTIBODY IS EFFECTIVE IN TREATING ARTHRITIS IN OBESE MICE
    Suzuki, M.
    Yoshida, H.
    Matsumoto, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 202 - 202
  • [49] TARGETED ANTI-INFLAMMATORY TREATMENT WITH ANTI-IL-6 MONOCLONAL ANTIBODY FOR CALCIUM MEDIATED ARRHYTHMIA SUBSTRATES IN HEART FAILURE
    Vasireddi, Sunil
    Sattayaprasert, Prasongchai
    Moravec, Christine
    Mackall, Judith
    Laurita, Kenneth
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 3662 - 3662
  • [50] ANALYSIS OF INTERLEUKIN 6 (IL-6)/IL-6 RECEPTOR SYSTEM USING MONOCLONAL ANTI-IL-6 ANTIBODIES
    SHIMAMURA, T
    TAKI, S
    HONDA, H
    YOKOTA, M
    ITO, S
    TAKAHARA, Y
    MOLECULAR IMMUNOLOGY, 1991, 28 (11) : 1155 - 1161
12345